Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Up 150.0% in July

Posted by Francis Steltz on Aug 14th, 2026

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 24,819 shares, an increase of 150.0% from the July 15th total of 9,927 shares. Currently, 1.2% of the shares of the stock are short sold. Based on an average daily trading volume, of 319,914 shares, the short-interest ratio is presently 0.1 days.

Biodexa Pharmaceuticals Stock Up 4.0%

Biodexa Pharmaceuticals stock opened at $1.56 on Friday. Biodexa Pharmaceuticals has a 52-week low of $1.02 and a 52-week high of $59.40. The firm’s fifty day moving average is $2.34 and its 200 day moving average is $3.80.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Biodexa Pharmaceuticals has an average rating of “Sell”.

View Our Latest Stock Analysis on Biodexa Pharmaceuticals

Institutional Trading of Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Armistice Capital LLC purchased a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned about 14.71% of Biodexa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 17.51% of the stock is owned by hedge funds and other institutional investors.

Biodexa Pharmaceuticals Company Profile

(Get Free Report)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.